PMID- 20421909
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Print)
IS  - 1176-6336 (Linking)
VI  - 6
DP  - 2010 Apr 15
TI  - Topical calcineurin inhibitors in systemic lupus erythematosus.
PG  - 95-101
AB  - Cutaneous lupus erythematosus (CLE) encompasses a variety of lesions that may be 
      refractory to systemic or topical agents. Discoid lupus erythematosus (DLE) and 
      subacute cutaneous lupus erythematosus (SCLE) are the most common lesions in 
      clinical practice. The topical calcineurin inhibitors, tacrolimus and 
      pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and 
      inhibit the proliferation and activation of T-cells and suppress immune-mediated 
      cutaneous inflammation. This article reviews the mechanism of action, efficacy, 
      adverse effects, and the recent concern about their possible carcinogenic effect. 
      Although the total number of patients is small and there is only one relevant 
      randomized controlled study, the data are encouraging. Many patients, previously 
      resistant to systemic agents or topical steroids, improved after four weeks of 
      treatment. DLE and SCLE lesions were less responsive, reflecting the chronicity 
      of the lesions, although more than 50% of patients still showed improvement. 
      Topical calcineurin inhibitors may be a safe and effective alternative to topical 
      steroids for CLE although the only approved indication is for atopic dermatitis.
FAU - Lampropoulos, Christos E
AU  - Lampropoulos CE
AD  - Lupus Research Unit, Rayne Institute, St. Thomas' Hospital, London, UK.
FAU - D'Cruz, David P
AU  - D'Cruz DP
LA  - eng
PT  - Journal Article
DEP - 20100415
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC2857609
OTO - NOTNLM
OT  - cutaneous lupus erythematosus
OT  - pimecrolimus
OT  - tacrolimus
OT  - topical calcineurin inhibitors
EDAT- 2010/04/28 06:00
MHDA- 2010/04/28 06:01
PMCR- 2010/04/15
CRDT- 2010/04/28 06:00
PHST- 2010/03/05 00:00 [received]
PHST- 2010/04/28 06:00 [entrez]
PHST- 2010/04/28 06:00 [pubmed]
PHST- 2010/04/28 06:01 [medline]
PHST- 2010/04/15 00:00 [pmc-release]
AID - tcrm-6-095 [pii]
AID - 10.2147/tcrm.s3193 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2010 Apr 15;6:95-101. doi: 10.2147/tcrm.s3193.